Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells

Urol Oncol. 2006 Sep-Oct;24(5):434-41. doi: 10.1016/j.urolonc.2005.08.010.

Abstract

Dendritic cells from patients with cancer are deficient in number and functional activity, leading to inadequate tumor immunosurveillance as a result of poor induction of T-cell antitumor responses. Loaded dendritic cell therapy is a vaccination strategy aimed at eliciting tumor antigen-specific, T-cell immune responses. Loaded dendritic cell therapy using prostatic acid phosphatase (APC8015; Provenge, Dendreon Corp., Seattle, WA) as an immunogen has shown a survival benefit in patients with metastatic hormone-refractory prostate cancer in a randomized phase III trial. This review will summarize the prostate cancer clinical trials using APC8015 and discuss the potential future role of APC8015 in prostate cancer treatment.

Publication types

  • Review

MeSH terms

  • Acid Phosphatase
  • Antigen-Presenting Cells / enzymology*
  • Antigen-Presenting Cells / immunology*
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Male
  • Prostatic Neoplasms / immunology*
  • Prostatic Neoplasms / therapy*
  • Protein Tyrosine Phosphatases / immunology*
  • Randomized Controlled Trials as Topic

Substances

  • Acid Phosphatase
  • prostatic acid phosphatase
  • Protein Tyrosine Phosphatases